Grundläggande statistik
| CIK | 1292087 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lotus Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| February 25, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 f8k021820lotuspharma.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2020 LOTUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-32581 (State or other jurisdict |
|
| May 11, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-32581 LOTUS PHARMACEUTICALS, INC. (Exact name of registrant as specifie |
|
| March 30, 2012 |
- FORM 12B-25 (NT 10-K) FOR 12-31-2011 NT 10-K 1 form12b-25.htm FORM 12B-25 (NT 10-K) FOR 12-31-2011 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-32581 NOTIFICATION OF LATE FILING CUSIP NUMBER 545715104 (Check one): X Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: DECEMBER 31, 2011 Transition Report on Form 10-K Transition Report on Fo |
|
| March 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| January 30, 2012 |
EX-10 2 ex10-1.htm LOAN TERMINATION AGREEMENT Exhibit 10.1 Loan Termination Agreement The loan agreement between Lotus Pharmaceuticals and Wu Lan Cha Bu Emergency Hospital (effective on Oct. 10, 2006), and the three-party loan assignment agreement between Lotus Pharmaceuticals, Lotus Pharmaceuticals CEO Mr. Zhongyi Liu, and Wu Lan Cha Bu Emergency Hospital (effective on Oct. 21, 2006), have reache |
|
| January 30, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2012 LOTUS PHARMACEUTICALS, INC. |
|
| January 11, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2012 LOTUS PHARMACEUTICALS, INC. |
|
| January 9, 2012 |
Exhibit 10.1 Business Transfer Agreement Party A: Liang Fang Pharmaceutical Co., Ltd. Party B: Cha You Qian Qi Meng Xin Vegetable Product Co., Ltd. After friendly discussion and negotiation between both parties, and with the goal of equality and mutual benefit, Liang Fang Pharmaceutical Co., Ltd. (Party A) and Meng Xin Vegetable Product Co., Ltd. (Party B) reach an agreement regarding the transfer |
|
| January 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2011 LOTUS PHARMACEUTICALS, INC. |
|
| November 16, 2011 |
Exhibit 99.1 Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results BEIJING , Nov. 11, 2011 /PRNewswire-Asia-FirstCall/ - Lotus Pharmaceuticals, Inc. (OTCBB: LTUS.OB - News) (?Lotus? or the ?Company?), a profitable developer, manufacturer and seller of medicine and drugs in the People?s Republic of China (?PRC?), today announced its financial results for the third fiscal quarter ende |
|
| November 16, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2011 LOTUS PHARMACEUTICALS, INC. |
|
| November 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-32581 LOTUS PHARM |
|
| August 17, 2011 |
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS Exhibit 99.1 Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results BEIJING, Aug. 15, 2011 /PRNewswire-Asia-FirstCall/ - Lotus Pharmaceuticals, Inc. (OTCBB:LTUS.ob - News) ("Lotus" or the "Company"), a profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced its financial results for the quarter ended June |
|
| August 17, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2011 LOTUS PHARMACEUTICALS, INC. |
|
| August 12, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-32581 LOTUS PHARMACEUT |
|
| May 18, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2011 LOTUS PHARMACEUTICALS, INC. |
|
| May 18, 2011 |
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS Exhibit 99.1 Lotus Pharmaceuticals Announces First Quarter Fiscal 2011 Financial Results BEIJING, May 16, 2011 /PRNewswire-Asia-FirstCall/ - Lotus Pharmaceuticals, Inc. (OTCBB:LTUS.ob - News) ("Lotus" or the "Company"), a profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced its financial results for the first quarter ended M |
|
| May 13, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-32581 LOTUS PHARMACEU |
|
| March 31, 2011 |
Exhibit 99.1 Lotus Pharmaceuticals Announces Fiscal 2010 Financial Results BEIJING, March 28, 2011 /PRNewswire-Asia-FirstCall/ - Lotus Pharmaceuticals, Inc. (OTC Bulletin Board:LTUS.ob - News) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced its financial results for the fourth |
|
| March 31, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2011 LOTUS PHARMACEUTICALS, INC. |
|
| March 28, 2011 |
Exhibit 14.1 CODE OF ETHICS AND BUSINESS CONDUCT FOR OFFICERS, DIRECTORS AND EMPLOYEES OF LOTUS PHARMACEUTICALS, INC. A goal of Lotus Pharmaceuticals, Inc. (the “Company”) and its subsidiaries is to promote professional and ethical conduct with respect to its business practices worldwide. This code provides ethical standards to which all of our executive officers, including our principal executive |
|
| March 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the fiscal year ended December 31, 2010 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the transition period from to Commission file number: 001-32581 LOTUS PHARMACEUTICALS, INC. (Exac |
|
| February 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2011 LOTUS PHARMACEUTICALS, INC. |
|
| February 23, 2011 |
AMENDMENT TO THE BYLAWS Lotus Pharmaceuticals, Inc. (a Nevada corporation) February 18, 2011 EX-3 2 ex3-1.htm AMENDMENT TO BYLAWS Exhibit 3.1 AMENDMENT TO THE BYLAWS OF Lotus Pharmaceuticals, Inc. (a Nevada corporation) February 18, 2011 The Bylaws of Lotus Pharmaceuticals, Inc., a Nevada corporation, are hereby amended as follows: Article VI, Section 5 shall be deleted in its entirety and replaced by the following which shall be inserted in lieu thereof: “Section 5. The stock transfer bo |
|
| December 22, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2010 LOTUS PHARMACEUTICALS, INC. |
|
| December 22, 2010 |
EX-99 2 ex99-1.htm CERTIFICATE OF CHANGE Exhibit 99.1 |
|
| November 10, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-32581 LOTUS PHARM |
|
| October 19, 2010 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Dear Dr. Liu, I have served as a Director since inception of LTUS. The transparency, communication, and operations of the public company are in question. I have made repeated requests for information that should be available to Directors. Most recently my request for a date of the next Board meeting has gone unanswered. Often you have sent me signature |
|
| October 19, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2010 LOTUS PHARMACEUTICALS, INC. |
|
| September 27, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 22, 2010 LOTUS PHARMACEUTICALS, INC. |
|
| September 27, 2010 |
Exhibit 99.1 Lotus Pharmaceuticals Announces Two Senior Management Appointments September 23, 2010 9:18 AM ET BEIJING, Sept. 23 /PRNewswire-Asia-FirstCall/ - Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the Company |
|
| September 9, 2010 |
Lotus Pharmaceuticals Announces Appointment of New Chief Financial Officer EX-99 2 ex99-1.htm PRESS RELEASE ISSUED ON 09-09-2010 Exhibit 99.1 Lotus Pharmaceuticals Announces Appointment of New Chief Financial Officer BEIJING - (Globe Newswire) - September 9, 2010 – Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) (“Lotus” or the “Company”), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People’s Republic of China ("PRC"), announced to |
|
| September 9, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2010 LOTUS PHARMACEUTICALS, INC. |
|
| September 3, 2010 |
EX-4 2 ex4-1.htm 2010 STOCK INCENTIVE PLAN Exhibit 4.1 2010 STOCK INCENTIVE PLAN 1. THE PLAN a) Purpose. This Lotus Pharmaceuticals, Inc. 2010 Stock Incentive Plan (the "Plan") is intended to benefit the stockholders of Lotus Pharmaceuticals, Inc. (the "Company") by providing a means to attract, retain and reward individuals who can and do contribute to the longer-term financial success of the Com |
|
| September 3, 2010 |
As filed with the Securities and Exchange Commission on September 3, 2010 - As filed with the Securities and Exchange Commission on September 3, 2010 Registration No. |
|
| August 13, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 form10q.htm FORM 10-Q FOR 06-30-2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis |
|
| July 23, 2010 |
Lotus Pharmaceuticals Terminates SEDA Exhibit 99.1 Lotus Pharmaceuticals Terminates SEDA BEIJING, July 22, 2010 - Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) (“Lotus” or the “Company”), a growing developer, manufacturer and seller of medicine and drugs in the People’s Republic of China (the “PRC”), announced today that it has entered into a termination agreement with Yorkville Global Master SPV Ltd.(“Yorkville”) whereby the |
|
| July 23, 2010 |
EX-10 2 ex101.htm TERMINATION AGREEMENT Exhibit 10.1 AGREEMENT AGREEMENT made as of this 20th day of July, 2010 by and among Yorkville Global Master SPV Ltd., a Cayman Islands exempt limited partnership, with a principal office located at 101 Hudson Street, Suite 3710, Jersey City, NJ 07302 (“Yorkville”), and Lotus Pharmaceuticals Inc., a corporation organized under the laws of Nevada, with a prin |
|
| July 23, 2010 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 20, 2010 LOTUS PHARMACEUTICALS, INC. |
|
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-32581 LOTUS PHARMACEU |
|
| March 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 form10k.htm FORM 10-K FOR 12-31-2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [√] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the fiscal year ended December 31, 2009 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the transition period from to Commission file number: |
|
| March 31, 2010 |
EX-10 20 ex1043.htm ASSIGNMENT OF AGREEMENT EXHIBIT 10.43 |
|
| March 5, 2010 |
EX-99.1 3 ltusex991.htm PRESS RELEASE ISSUED BY LOTUS PHARMACEUTICALS, INC. ON MARCH 3, 2010 EXHIBIT 99.1 YA Global Master SPV Ltd invests up to US$10,000,000 in Lotus Pharmaceutical, Inc. through Equity Line Facility YA Global Master SPV Ltd's makes its first Chinese investment for the Year of the Tiger with an investment in the fast growing healthcare sector in China (Beijing/Hong Kong/New Jerse |
|
| March 5, 2010 |
STANDBY EQUITY DISTRIBUTION AGREEMENT EX-10.1 2 ltusex101.htm STANDBY EQUITY DISTRIBUTION AGREEMENT, DATED AS OF MARCH 3, 2010, BY AND BETWEEN LOTUS PHARMACEUTICALS, INC. AND YA GLOBAL MASTER SPV LTD EXHIBIT 10.1 STANDBY EQUITY DISTRIBUTION AGREEMENT THIS AGREEMENT dated as of the 3rd day of March 2010 (this “Agreement”) between YA GLOBAL MASTER SPV LTD., a Cayman Islands exempt limited partnership (the “Investor”), and LOTUS PHARMACE |
|
| March 5, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 3, 2010 LOTUS PHARMACEUTICALS, INC. |
|
| January 15, 2010 |
Lotus Pharmaceuticals Announces Key Changes Exhibit 99.1 Lotus Pharmaceuticals Announces Key Changes BEIJING, January 15, 2009 - Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) (?Lotus? or the ?Company?), a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People?s Republic of China (?PRC?), today reported that its newly engaged auditor is Friedman LLP and legal counse |
|
| January 15, 2010 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2010 LOTUS PHARMACEUTICALS, INC. |
|
| January 15, 2010 |
EX-16 2 ex161.htm LETTER DATED JANUARY 13, 2010 Exhibit 16.1 January 13, 2010 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for Lotus Pharmaceuticals Inc. (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” o |
|
| November 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 lotusform10-q.htm FORM 10-Q FOR 09-30-2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro |
|
| August 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-32581 LOTUS PHARMACEUT |
|
| May 21, 2009 |
Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results EX-99 2 ex991.htm PRESS RELEASE DATED 05-18-2009 EXHIBIT 99.1 Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results BEIJING, May 18 /PRNewswire-Asia-FirstCall/ - Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) (“Lotus” or the “Company”) a company that controls and operates pharmaceutical companies in the People’s Republic of China (“PRC”), today reported its financial res |
|
| May 21, 2009 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8-k.htm FORM 8-K FOR 05-18-2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 18, 2009 LOTUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-32581 20-0507918 (State or other juri |
|
| May 15, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-32581 LOTUS PHARMACEU |
|
| May 14, 2009 |
May 13, 2009 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Sasha Parikh Re: Lotus Pharmaceuticals, Inc. Item 4.01 Form 8-K filed April 29, 2009 File No. 001-32581 Dear Ms. Parikh: This is in reply to your letter of comment dated May 5, 2009 (the “Comment Letter”), regarding Item 4.01 of the Form 8-K (the “Form 8-K) filed by Lotus Pharmaceuticals, Inc. (the |
|
| May 14, 2009 |
EX-16.1 3 v149510ex16-1.htm EXHIBIT 16.1 May 12, 2009 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Sasha Parikh Dear Ms. Sasha Parikh: Lotus Pharmaceuticals, Inc. (the “Company”) provided to us a copy of the Company’s revised Current Report on Form 8-K/A (the “Form 8-K/A”) according to Securities and Exchange Commission’s comment letter dated May 5, 2009. |
|
| May 14, 2009 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A AMENDMENT NO. |
|
| April 29, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2009 LOTUS PHARMACEUTICALS, INC. |
|
| April 29, 2009 |
Exhibit 99.1 April 24, 2009 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: Lotus Pharmaceuticals, Inc. (the “Company”) provided to us a copy of the Company’s response to Item 4.01 of Form 8-K, dated April 24, 2009. We have read the Company’s statements included under Item 4.01 of its Form 8-K and we agree with such statements insofar as they relate to our firm. Ver |
|
| April 29, 2009 |
Exhibit 99.2 Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results -Expands into Inner Mongolia to fuel future growth - Revenues of $73.8 million - Gross Profit of $33.4 million - Net income of $12.8 million or $0.27 per diluted share BEIJING, April 22, 2009 - Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS.OB, “Lotus” or the “Company”) today reported its strong 2008 results with |
|
| April 15, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 v14626310k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the fiscal year ended December 31, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the transition period from to Commission file number: 001-32581 LOTUS PHARMACEU |
|
| March 31, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-32581 NOTIFICATION OF LATE FILING CUSIP NUMBER 545715104 (Check one): X Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: DECEMBER 31, 2008 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Fo |
|
| February 18, 2009 |
EXHIBIT 99.1 Lotus Pharmaceuticals, Inc. CCG Investor Relations, Inc. Mr. Adam Wasserman, CFO Mr. Crocker Coulson, President Phone: +877-801-0344 Phone: +1-646-213-1915 [email protected] [email protected] http://www.lotuseast.com http://www.ccgirasia.com Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug BEIJING, Feb 18, 2009 - Lotus Pha |
|
| February 18, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 2, 2008 LOTUS PHARMACEUTICALS, INC. |
|
| February 18, 2009 |
Yipubishan New Drug Certificate and Intellectual Property Right Transfer Contract EX-10 2 ex1041.htm CONTRACT EXHIBIT 10.41 Yipubishan New Drug Certificate and Intellectual Property Right Transfer Contract Party A: Beijing Yipuan Bio-Medical Technology Co., Ltd. Part y B: Beijing Liang Fang Pharmaceutical, Co., Ltd. This contract is established based on the rules of the Technology Contract Law of People’s Republic of China and the mutual agreement of both parties. I. Party A’s |
|
| November 21, 2008 |
Lotus Pharmaceuticals Announces Third Quarter 2008 Results EX-99 2 ex991.htm PRESS RELEASE DATED 11-18-2008 Exhibit 99.1 Contact: Lotus Pharmaceuticals, Inc. CCG Investor Relations Inc. Mr. Adam Wasserman, CFO Mr. Crocker Coulson, President Phone: (877) 801-0344 Phone: (646) 213-1915 (New York) E-mail: [email protected] E-mail: [email protected] Website: http://www.lotuseast.com Website: http://www.ccgir.com Lotus Pharmaceuticals Announces Third |
|
| November 21, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2008 LOTUS PHARMACEUTICALS, INC. |
|
| November 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-32581 LOTUS PHARM |
|
| August 21, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 18, 2008 LOTUS PHARMACEUTICALS, INC. |
|
| August 21, 2008 |
Lotus Pharmaceuticals Announces Second Quarter 2008 Results Exhibit 99.1 Contact: Lotus Pharmaceuticals, Inc. CCG Investor Relations Inc. Mr. Adam Wasserman, CFO Mr. Crocker Coulson, President Phone: (877) 801-0344 Phone: (646) 213-1915 (New York) E-mail: [email protected] E-mail: [email protected] Website: http://www.lotuseast.com Website: http://www.ccgir.com Lotus Pharmaceuticals Announces Second Quarter 2008 Results Beijing, China, August 18 2 |
|
| August 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30451 LOTUS PHARMACEUT |
|
| July 25, 2008 |
Lotus Pharmaceuticals, Inc. 4,482,749 shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-150879 PROSPECTUS Lotus Pharmaceuticals, Inc. 4,482,749 shares of Common Stock This prospectus relates to periodic offers and sales of 4,482,749 shares of our common stock by the selling security holders, which includes: ? 1,609,196 shares issuable upon the possible conversion of shares of Series A Convertible Redeemable Preferred Stock; and ? |
|
| July 23, 2008 |
Lotus Pharmaceuticals, Inc. 16 Cheng Zhuang Road Feng Tai District Beijing 100071 China Lotus Pharmaceuticals, Inc. 16 Cheng Zhuang Road Feng Tai District Beijing 100071 China 86-10-63899868 July 23, 2008 ‘CORRESP’ United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jennifer Riegel Mail Stop 6010 Re: Lotus Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-150879 Ladies and Gentlemen: The undersigned registrant here |
|
| July 18, 2008 |
SCHNEIDER WEINBERGER & BEILLY, LLP 2200 Corporate Boulevard, N.W. Suite 201 Boca Raton, Florida 33431 telephone (561) 362-9595 telecopier (561) 362-9612 email: [email protected] July 18, 2008 ‘CORRESP’ United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedel, Assistant Director Jennifer Riegel Suzanne Hayes, Branch Chief Re: Lotus Pharmaceut |
|
| July 18, 2008 |
As filed with the Securities and Exchange Commission on July 18, 2008 Registration No. |
|
| July 17, 2008 |
EX-10 2 ex1040.htm ENGLISH TRANSLATION OF AGREEMENT DATED 06-03-2008 EXHIBIT 10.40 English translation of Agreement dated June 3, 2008 by and between Beijing Liang Fang Pharmaceutical Co., Ltd., a Chinese limited liability company, and Cha You Qian Qi Economy Commission. Agreement Party A: Cha You Qian Qi Economy Commission Party B: Liang Fang Pharmaceuticals Limited Liability Corporation Party B |
|
| July 17, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2008 LOTUS PHARMACEUTICALS, INC. |
|
| June 20, 2008 |
As filed with the Securities and Exchange Commission on June 20, 2008 Registration No. |
|
| June 20, 2008 |
SCHNEIDER WEINBERGER & BEILLY, LLP 2200 Corporate Boulevard, N.W. Suite 201 Boca Raton, Florida 33431 telephone (561) 362-9595 telecopier (561) 362-9612 email: [email protected] June 20, 2008 ‘CORRESP’ United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Riedel, Assistant Director Jennifer Riegel Suzanne Hayes, Branch Chief Re: Lotus Pharmaceut |
|
| June 16, 2008 |
As filed with the Securities and Exchange Commission on June 16, 2008 Registration No. |
|
| May 30, 2008 |
EX-99 4 ex991.htm PRESS RELEASE DATED MAY 19, 2008 EXHIBIT 99.1 Lotus Pharmaceuticals, Inc. Obtains Patent and Exclusive Production Rights to Laevo-Bambutero Asthma Treatment BEIJING, China, May 19 /Xinhua-PRNewswire-FirstCall/ - Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS - News; “Lotus” or the “Company”), a pharmaceutical company in the People’s Republic of China (“PRC”), today announc |
|
| May 30, 2008 |
EX-10 2 ex1039.htm TECHNOLOGY TRANSFER AGREEMENT DATED 04-25-2008 EXHIBIT 10.39 English translation of Technology Transfer Agreement dated April 25, 2008 by and between Bei Jing En Ze Jia Shi Pharmaceuticals LTD and Dong Guan Kai Fa Biologicals Medicine LTD Technology Transfer Agreement Party A: Bei Jing En Ze Jia Shi Pharmaceutics LTD Party B: Dong Guan Kai Fa Biologicals Medicine LTD I: Project |
|
| May 30, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2008 LOTUS PHARMACEUTICALS, INC. |
|
| May 30, 2008 | ||
| May 30, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2008 LOTUS PHARMACEUTICALS, INC. |
|
| May 30, 2008 |
EX-99 4 ex992.htm PRESS RELEASE ISSUED MAY 30, 2008. EXHIBIT 99.2 Contact: Lotus Pharmaceuticals, Inc. CCG Elite Investor Relations Inc. Mr. Adam Wasserman, CFO Mr. Crocker Coulson, President Phone: (877) 801-0344 Phone: +1-646-213-1915 (New York) [email protected] Email: [email protected] Website: www.ccgelite.com Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make G |
|
| May 30, 2008 |
EX-99 2 ex991.htm TRANSCRIPT OF CONFERENCE CALL HELD MAY 27, 2008 EXHIBIT 99.1 Final Transcript LOTUS PHARMACEUTICALS INC: LOTUS PHARMACEUTICALS INC Q1 EARNINGS CONFERENCE CALL May 27, 2008/10:00 a.m. EDT SPEAKERS Crocker Coulson Dr. Zhongyi Liu Adam Wasserman IN CONFIDENCE Final Transcript LOTUS PHARMACEUTICALS INC: LOTUS PHARMACEUTICALS INC Q1 EARNINGS CONFERENCE CALL May 27, 2008/10:00 a.m. EDT |
|
| May 22, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 21, 2008 LOTUS PHARMACEUTICALS, INC. |
|
| May 22, 2008 |
Lotus Pharmaceuticals, Inc. Announces First Quarter 2008 Results EX-99 2 ex991.htm PRESS RELEASE DATED MAY 21, 2008 Exhibit 99.1 Contact: Lotus Pharmaceuticals, Inc. CCG Elite Investor Relations Inc. Mr. Adam Wasserman, CFO Mr. Crocker Coulson, President Phone: (877) 801-0344 Phone: +1-646-213-1915 (New York) [email protected] Email: [email protected] Website: www.ccgelite.com For Immediate Release Lotus Pharmaceuticals, Inc. Announces First Quarter 20 |
|
| May 20, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Mark One) FORM 10-Q [√] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2008 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 000-30451 LOTUS PHARM |
|
| May 16, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-32581 CUSIP NUMBER: 545715104 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2008 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tran |
|
| May 13, 2008 |
LOTUS PHARMACEUTICALS, INC. 16 Cheng Zhuang Road Feng Tai District Beijing 100071 China LOTUS PHARMACEUTICALS, INC. 16 Cheng Zhuang Road Feng Tai District Beijing 100071 China ‘CORRESP’ May 13, 2008 Via Edgar United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jim B. Rosenberg, Senior Assistant Chief Accountant Mr. Jim Atkinson, Accounting Branch Chief Mr. James Peklenk, Staff Accountant Re: Lotus Pharmaceuticals, Inc. (the “Compa |
|
| May 13, 2008 |
Code of Business Conduct and Ethics * Exhibit 14.1 LOTUS PHARMACEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS (Adopted by the Board of Directors on April 23, 2008) Introduction This Code of Business Conduct and Ethics covers a wide range of business practices and procedures. It does not cover every issue that may arise but it sets out basic principles to guide all employees of Lotus Pharmaceuticals, Inc. (the “Company”). All of our |
|
| May 13, 2008 |
As filed with the Securities and Exchange Commission on May 13, 2008 Registration No. |
|
| April 24, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 21, 2008 LOTUS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-32581 20-0507918 (State or other Jurisdiction (Commission (IRS Employer of |
|
| April 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the fiscal year ended December 31, 2007 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the transition period from to Commission file number: 001-32581 LOTUS PHARMACEUTICALS, INC. - (Na |
|
| March 31, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-32581 CUSIP NUMBER: 545715104 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2007 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o T |
|
| March 10, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* LOTUS PHARMACEUTICALS, INC (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 784097107 (CUSIP Number) China West, LLC 201 South Biscayne Boulevard 28th Floor, Miami, FL 33131 (Name, Address and Telephone Number of P |
|
| February 29, 2008 |
Form of certificate of Lotus Pharmaceuticals, Inc.’s preferred stock (2) Exhibit 4.2 |
|
| February 29, 2008 |
Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2008 LOTUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Nevada 001-32581 20-0507918 (State or other jurisdiction of incorporation or organ |
|
| February 26, 2008 |
Lotus Pharmaceuticals Raises $5 Million in Private Placement Exhibit 99.3 For Immediate Release Contact: Lotus Pharmaceuticals, Inc. CCG Elite Investor Relations Inc. Mr. Adam Wasserman, CFO Mr. Crocker Coulson, President Phone: +1-877-801-0344 Phone: +1-646-213-1915 (New York) Email: [email protected] Email: [email protected] Lotus Pharmaceuticals Raises $5 Million in Private Placement Beijing, China – February, 26, 2008 – Lotus Pharmaceuticals, I |
|
| February 26, 2008 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2008 LOTUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Nevada 001-32581 20-0507918 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| February 26, 2008 |
Exhibit 99.2 Schedule Prepared in Accordance with Instruction 2 to Item 601 of Regulation S-K The warrants dated February 25, 2008 are substantially identical in all material respects except as to the warrantholder and the number of shares for which warrant can be exercised. Holder Shares for which Warrant can be Exercised Sansar Capital Master Fund, L.P. 1,149,425 Sansar Capital Special Opportuni |
|
| February 26, 2008 |
LOTUS PHARMACEUTICALS, INC. CONVERTIBLE REDEEMABLE PREFERRED SHARE AND WARRANT PURCHASE AGREEMENT Exhibit 99.1 LOTUS PHARMACEUTICALS, INC. CONVERTIBLE REDEEMABLE PREFERRED SHARE AND WARRANT PURCHASE AGREEMENT This Convertible Redeemable Preferred Share and Warrant Purchase Agreement (this “Agreement”) is dated as of February 25, 2008, among (i) Lotus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), (ii) Dr. Liu Zhong Yi and Mrs. Song Zhenghong (the “Founders”), (iii) Sansar Capital |
|
| February 21, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB/A (Amendment No. 2) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32581 |
|
| February 21, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3 |
|
| February 21, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32581 |
|
| February 21, 2008 |
LOTUS PHARMACEUTICALS, INC. 7900 Glades Road Suite 420 Boca Raton, Florida 33484 LOTUS PHARMACEUTICALS, INC. 7900 Glades Road Suite 420 Boca Raton, Florida 33484 ‘CORRESP’ February 21, 2008 Via Edgar United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jim Atkinson, Branch Chief Mr. Jim B. Rosenberg, Senior Assistant Chief Accountant Mr. James Peklenk, Staff Accountant Re: Lotus Pharmaceuticals, Inc. (the “Company”) Form 10- |
|
| February 20, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-KSB/A AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-KSB/A AMENDMENT NO. |
|
| February 20, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32581 |
|
| February 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 11, 2008 LOTUS PHARMACEUTICALS, INC. |
|
| December 6, 2007 |
Exhibit 99.2 |
|
| December 6, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| December 5, 2007 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2007 LOTUS PHARMACEUTICALS, INC. |
|
| December 5, 2007 |
Exhibit 99.1 |
|
| December 5, 2007 |
December 2007This presentation contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. |
|
| November 20, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 20, 2007 LOTUS PHARMACEUTICALS, INC. |
|
| November 20, 2007 |
Exhibit 99.1 Lotus Pharmaceuticals Releases Third Quarterly Report Showing $37.6 Million in Revenues and $6 Million in Net Profits BEIJING, Nov. 20, 2007 (PRIME NEWSWIRE) - Lotus Pharmaceuticals, Inc. (OTC BB:LTUS.OB - News) released its third quarter results, in a 10-QSB filing with the S.E.C. Financial results showed revenues topping $37.6 million and net profits of $6 million for the nine month |
|
| November 19, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32581 LOTUS PHARMACEU |
|
| November 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-32581 CUSIP NUMBER: 545715104 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2007 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o |
|
| November 5, 2007 |
LOTUS PHARMACEUTICALS, INC. 9700 Glades Road, Suite 420 Boca Raton, Florida 33434 LOTUS PHARMACEUTICALS, INC. 9700 Glades Road, Suite 420 Boca Raton, Florida 33434 Telephone (877) 801-0344 ‘CORRESP’ November 5, 2007 United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jim B. Rosenberg James Penlenk Re: Lotus Pharmaceuticals, Inc. Form 10-KSB for the Fiscal Year Ended December 31, 2006 For 10-QSB for the Six Months Ended June 30, |
|
| October 18, 2007 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-142355 Prospectus Supplement No. 2 dated October 18, 2007 to Prospectus dated May 7, 2007 LOTUS PHARMACEUTICALS, INC. 3,500,000 shares of Common Stock This Prospectus Supplement, together with the prospectus dated May 7, 2007 and Prospectus Supplement No. 1 dated May 24, 2007, is required to be delivered by certain holder of the above-reference |
|
| August 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32581 LOTUS PHARMACEUTICAL |
|
| May 24, 2007 |
424B3 1 v076774424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-142355 Prospectus Supplement dated May 24, 2007 (To Prospectus dated May 7, 2007 and filed on May 7, 2007 - File No. 333-142355) LOTUS PHARMACEUTICALS, INC. (formerly known as Cyber Merchants Exchange, Inc.) PROSPECTUS 3,500,000 shares of Common Stock This Prospectus Supplement, together with the Prospectus listed above |
|
| May 21, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-QSB (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32581 LOTUS PHARMACEUTICA |
|
| May 7, 2007 |
3,500,000 SHARES LOTUS PHARMACEUTICALS, INC. COMMON STOCK Filed Pursuant to Rule 424(b)(3) Registration No. 333-142355 PROSPECTUS 3,500,000 SHARES LOTUS PHARMACEUTICALS, INC. COMMON STOCK This prospectus relates to the sale of up to 3,500,000 shares of our Common Stock, par value $0.001 per share (“Common Stock”), consisting of (i) 2,750,000 shares issuable upon conversion of a Secured Convertible Note issued to Longview Fund LP (“Longview”); and (ii) 25 |
|
| April 25, 2007 |
As filed with the Securities and Exchange Commission on April 25, 2007 (Registration No. |
|
| April 25, 2007 |
EXHIBIT 21.1 SUBSIDIARIES OF THE COMPANY 1. Lotus Pharmaceutical International, Inc., a Nevada corporation |
|
| April 25, 2007 |
Exhibit 16.1 April 25, 2007 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: S.E. Asia Trading Company, Inc. (the ?Company?) provided to us a copy of the Company?s response to Item 4.01 of Form 8-K, dated April 25, 2007. We have read the Company?s statements included under Item 4.01 of its Form 8-K and we agree with such statements insofar as they relate to our firm. |
|
| April 25, 2007 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2007 (November 6, 2006) LOTUS PHARMACEUTICALS, INC. |
|
| April 25, 2007 |
LOTUS PHARMACEUTICALS, INC. 9700 Glades Road, Suite 420 Boca Raton, Florida 33434 CORRESP 3 filename3.htm LOTUS PHARMACEUTICALS, INC. 9700 Glades Road, Suite 420 Boca Raton, Florida 33434 Telephone (877) 801-0344 'CORRESP' April 25, 2007 United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Vanessa Robertson Re: S.E. Asia Trading Company, Inc. (Currently known as Lotus Pharmaceuticals, Inc.) Item 4.01 Form 8-K Filed November 13, 2 |
|
| April 17, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-KSB (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-KSB (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the fiscal year ended December 31, 2006 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 For the transition period from to Commission file number: 001-32581 LOTUS PHARMACEUTICALS, INC. |
|
| April 17, 2007 | ||
| April 17, 2007 |
Loan Agreement Party A: Beijing Liang Fang Pharmaceutical Co., Ltd. Party B: Wu Lan Cha Bu Emergency Hospital Center 1, Type: 2, Usage: construction of new hospital ward 3, Sum: 30 Million RMB 4, Condition 1. Party B agree after the construction of new hospital ward, Party B will assigned Party A to be the only provider for all the medicine and disposable medical treatment apparatus, corporation p |
|
| April 17, 2007 | ||
| April 17, 2007 | ||
| April 17, 2007 |
EX-10.24 8 v071661ex10-24.htm CONTRACT This contract is signed on October 10th, 2006 by the following parties. Party A: Wu Lan Cha Bu Emergency Hospital Center Party B: Beijing Liang Fang pharmaceutical Co. Ltd.. Herein, Wu Lan Cha Bu Emergency Hospital Center (Party A) loaned 30 Million from Beijing Liang Fang pharmaceutical Co. Ltd. (Party B) for the construction of new hospital ward. Herein, bo |
|
| April 17, 2007 |
EX-21.1 21 v071661ex21-1.htm EXHIBIT 21.1 SUBSIDIARIES OF THE COMPANY 1. Lotus Pharmaceutical International, Inc., a Nevada corporation. |
|
| April 17, 2007 | ||
| February 15, 2007 |
EXH. 10.1 FORM OF SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT EXH. 10.1 FORM OF SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of February 12, 2007, by and among Lotus Pharmaceuticals, Inc. (formerly known as S.E. Asia Trading Company, Inc.), a Nevada corporation (the “Company”), and the subscribers identified on the signature page hereto (each a “Subscriber” and collectively “Subscribers”). WHEREAS, th |
|
| February 15, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2007 (February 12, 2007) LOTUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Nevada 001-32581 20-0507518 (State or other jurisdiction of incorp |
|
| February 15, 2007 |
EXH. 10.6 GUARANTY 1. Identification. This Guaranty (the "Guaranty"), dated as of February 12, 2007, is entered into by Lotus Pharmaceutical International, Inc., a Nevada corporation (and wholly owned subsidiary of Lotus Pharmaceuticals, Inc., a Nevada corporation), En Ze Jia Shi Pharmaceutical CO., Ltd., a People’s Republic of China corporation, Liang Fang Pharmaceutical CO., Ltd., a People’s Rep |
|
| February 15, 2007 |
EXH. 10.7 CEO SHARE PLEDGE AGREEMENT EXH. 10.7 CEO SHARE PLEDGE AGREEMENT CEO SHARE PLEDGE AGREEMENT (this "Agreement"), dated as of February 12, 2007, made by Liu Zhong Yi, an individual with a principal place of residence at No. 3, Fengtai Yungang Town Gaonan Li, Beijing, China 100074 (the "Pledgor"), in favor of S. Michael Rudolph, in his capacity as collateral agent (in such capacity, the "Collateral Agent") for the "Buyers" (as |
|
| February 15, 2007 |
EX-10.4 5 v066207ex10-4.htm EXH. 10.4 SECURITY AGREEMENT 1. Identification. This Security Agreement (the "Agreement"), dated as of February 12, 2007, is entered into by and between Lotus Pharmaceuticals, Inc., a Nevada corporation ("Parent"), Lotus Pharmaceutical International, Inc. (“Subsidiary”), En Ze Jia Shi Pharmaceutical CO., Ltd., a People’s Republic of China corporation, Liang Fang Pharmac |
|
| February 15, 2007 |
EXH. 10.5 PLEDGE AGREEMENT PLEDGE AGREEMENT (this "Agreement"), dated as of February 12, 2007, made by Lotus Pharmaceutical International, Inc., a Nevada corporation (the "Pledgor"), in favor of S. Michael Rudolph, in his capacity as collateral agent (in such capacity, the "Collateral Agent") for the "Buyers" (as defined below) party to the Subscription Agreement, dated as of February 12, 2007 (as |
|
| February 15, 2007 |
EX-10.3 4 v066207ex10-3.htm EXHIBIT 10.3 FORM OF NOTE THIS NOTE AND THE COMMON SHARES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS NOTE AND THE COMMON SHARES ISSUABLE UPON CONVERSION OF THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE UNDER |
|
| February 15, 2007 |
EXH. 10.8 DIRECTOR SHARE PLEDGE AGREEMENT EX-10.8 9 v066207ex10-8.htm EXH. 10.8 DIRECTOR SHARE PLEDGE AGREEMENT DIRECTOR SHARE PLEDGE AGREEMENT (this "Agreement"), dated as of February 12, 2007, made by Song Zhenghong, an individual with a principal place of residence at (the "Pledgor"), in favor of S. Michael Rudolph, in his capacity as collateral agent (in such capacity, the "Collateral Agent") for the "Buyers" (as defined below) party |
|
| February 15, 2007 |
EXH. 10.2 FORM OF WARRANT THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR AN OPINION OF COUNSEL RE |
|
| January 18, 2007 |
RICHARDSON & PATEL LLP 10900 Wilshire Boulevard Suite 500 Los Angeles, CA 90024 Telephone (310) 208-1182 Facsimile (310) 208-1154 January 17, 2007 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 18, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ý Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement LOTUS PHARMACEUTICALS, INC. (Name of |
|
| January 18, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ý Definitive Information Statement LOTUS PHARMACEUTICALS, INC. (Name of |
|
| January 3, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ý Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement LOTUS PHARMACEUTICALS, INC. (Name of |
|
| December 19, 2006 |
EX-3.1 2 exhibit3one.htm CERTIFICATE OF AMENDMENT |
|
| December 19, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 18, 2006 (December 11, 2006) LOTUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Nevada 001-32581 20-0507518 (State or other jurisdiction of incorp |
|
| November 28, 2006 |
Table of Contents OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
|
| November 14, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission file number 001-32581 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2006 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ |
|
| November 13, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement S.E. ASIA TRADING COMPANY, INC |
|
| November 13, 2006 |
EX-16.1 2 exhibit16one.htm LETTER FROM LBB & ASSOCIATES LTD., LLP Exhibit 16.1 November 6, 2006 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: S.E. Asia Trading Company, Inc. (the “Company”) provided to us a copy of the Company’s response to Item 4.01 of Form 8-K, dated November 6, 2006. We have read the Company’s statements included under Item 4.01 of its Form 8-K |
|
| November 13, 2006 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2006 S. |
|
| October 30, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ý Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement S.E. ASIA TRADING COMPANY, INC. (Nam |
|
| October 10, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* S.E. ASIA TRADING COMPANY, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 784097107 (CUSIP Number) Liu Zhong Yi 7900 Glades Road, Suite 420 Boca Raton, Florida 33434 (Name, Address and Telephone Number of Per |
|
| October 10, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* S.E. ASIA TRADING COMPANY, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 784097107 (CUSIP Number) Song Zhenghong 7900 Glades Road, Suite 420 Boca Raton, Florida 33434 (Name, Address and Telephone Number of P |
|
| October 10, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* S.E. ASIA TRADING COMPANY, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 784097107 (CUSIP Number) Shaohua Tan Suite 310, Building B, Ideal Plaza No. 3 Danling Street, Haidian District Beijing 100080, China ( |
|
| October 5, 2006 |
OPERATING AGREEMENT (English Translation) EX-99.3 4 v054112ex99-3.htm OPERATING AGREEMENT (English Translation) This Operating Agreement (this “Agreement”) is dated September 6, 2006, and is entered into in Beijing, China by and among Lotus Pharmaceutical International, Inc., a company incorporated under the laws of the State of Nevada, the United States, located at Boca Corporate Plaza, 7900 Glades Road, Suite 420, Boca Raton, Florida 33 |
|
| October 5, 2006 |
LIANG FANG PHARMACEUTICALS CO., LTD. AND COMBINED AFFILIATE COMBINED FINANCIAL STATEMENTS June 30, 2006 LIANG FANG PHARMACEUTICALS CO., LTD. AND COMBINED AFFILIATE INDEX TO UNAUDITED COMBINED FINANCIAL STATEMENTS CONTENTS Combined Financial Statements: Combined Balance Sheet - June 30, 2006 (Unaudited) F-2 Combined Statements of Operations (Unaudited) For the six months ended June 30, 2006 and 200 |
|
| October 5, 2006 |
LOAN CONTRACT Contract Number: BORROWER: Beijing En Ze Jia Shi Pharmaceutical Co., Ltd LENDER: Song, Zhenghong In accordance with provisions of Contract Law of the Peoples Republic of China and Bank of China, after reviewing the status and the request of the Borrower, the Lender agrees to grant the Borrower a line of credit on 24,000,000 RMB. The Borrower and Lender through friendly negotiation, h |
|
| October 5, 2006 |
LEASE CONTRACT Lesser (hereinafter referred to as Party A): Beijing Qiji investment and management center Lessee (hereinafter referred to as Party B): Liangfang Pharmaceutical Co. |
|
| October 5, 2006 |
S.E. ASIA TRADING COMPANY, INC. AND SUBSIDIARY PRO FORMA COMBINED FINANCIAL STATEMENTS JUNE 30, 2006 (UNAUDITED) S.E. ASIA TRADING COMPANY, INC. AND SUBSIDIARY Index to Unaudited Pro Forma Combined Financial Statements Pages Introduction to Unaudited Pro Forma Combined Financial Statements 2-3 Unaudited Pro Forma Combined Balance Sheet - June 30, 2006 4 Unaudited Pro Forma Combined Statement of Op |
|
| October 5, 2006 |
Thomas G. Miller 1545 E. Interstate 30 Rockwall, Texas 75087 EX-99.11 12 v054112ex99-11.htm Thomas G. Miller 1545 E. Interstate 30 Rockwall, Texas 75087 September 21, 2006 S.E. Asia Trading Company, Inc 1545 E. Interstate 30 Rockwall, Texas 75087 Dear Sir or Madam: Reference is made to the Share Exchange Agreement dated September 6, 2006 (the “Agreement”), between S.E. Asia Trading Company, Inc. (“SEAA”), Lotus Pharmaceutical International, Inc., (“Lotus”), |
|
| October 5, 2006 |
LEASE CONTRACT Lesser (hereinafter referred to as Party A): Beijing Aoshikai Peace Lane Shopping center Lessee (hereinafter referred to as Party B): Drugstore (Peace Lane Branch) of Liangfang Pharmaceutical Co. |
|
| October 5, 2006 |
EQUITY PLEDGE AGREEMENT (English Translation) EX-99.2 3 v054112ex99-2.htm EQUITY PLEDGE AGREEMENT (English Translation) This Equity Pledge Agreement (hereinafter this “Agreement”) is dated September 6, 2006, and is entered into in Beijing, China between Lotus Pharmaceutical International, Inc. a company incorporated under the laws of the State of Nevada, the United States, located at Boca Corporate Plaza, 7900 Glades Road, Suite 420, Boca Rat |
|
| October 5, 2006 |
Proxy Agreement This Proxy Agreement (the “Agreement”) is entered into as of September 6, 2006 among the following parties: Party A: Lotus Pharmaceutical International, Inc. |
|
| October 5, 2006 |
EX-99.97 33 v054112ex99-97.htm LIANG FANG PHARMACEUTICALS CO., LTD. AND COMBINED AFFILIATE COMBINED FINANCIAL STATEMENTS December 31, 2005 LIANG FANG PHARMACEUTICALS CO., LTD. AND COMBINED AFFILIATE INDEX TO COMBINED FINANCIAL STATEMENTS CONTENTS Report of Independent Registered Public Accounting Firm F-2 Combined Financial Statements: Combined Balance Sheet F-3 Combined Statements of Operations F |
|
| October 5, 2006 |
OPTION AGREEMENT (English translation) OPTION AGREEMENT (English translation) This Operating Agreement (this ?Agreement?) is dated September 6, 2006, and is entered into in Beijing, China between Lotus Pharmaceutical International, Inc. |
|
| October 5, 2006 |
LEASE CONTRACT Lesser (hereinafter referred to as Party A): Beijing Aoshikai Peace Lane Shopping center Lessee (hereinafter referred to as Party B): Liangfang Pharmaceutical Co. |
|
| October 5, 2006 |
GENERAL PARTNERSHIP AGREEMENT This Agreement is made and entered into as of the 15 day of March, 2006 between Genesis Equity Partners, LLC, a US limited liability partnership (referred to as ?GEP?) and Liang Fang Pharmaceutical, Ltd. |
|
| October 5, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 4, 2006 (September 28, 2006) S.E. ASIA TRADING COMPANY, INC. (Exact name of registrant as specified in Charter) Nevada 001-32581 20-0507518 (State or other jurisdiction of inc |
|
| October 5, 2006 |
LEASE CONTRACT Lesser (hereinafter referred to as Party A): Beijing Fengtai District 2nd Sanatorium of General Logistics of P. |
|
| October 5, 2006 |
EX-99.21 24 v054112ex99-21.htm LEASE CONTRACT Lesser (hereinafter referred to as Party A): LIU, ZHONGYI Lessee (hereinafter referred to as Party B): Liangfang Pharmaceutical Co. Ltd Party A and Party B have reached an agreement through friendly consultation to conclude the following contract. 1. Location of the premises Party A will lease to Party B the premises and attached facilities owned by it |
|
| October 5, 2006 |
EX-99.22 25 v054112ex99-22.htm LEASE CONTRACT Lesser (hereinafter referred to as Party A): Real Estate Management Agency of General Logistics of P.L.A. Lessee (hereinafter referred to as Party B): Drugstore (Wanshou Road Branch) of Liangfang Pharmaceutical Co. Ltd Party A and Party B have reached an agreement through friendly consultation to conclude the following contract. 1. Location of the prem |
|
| October 5, 2006 |
LOAN CONTRACT Contract Number: BORROWER: Beijing En Ze Jia Shi Pharmaceutical Co., Ltd LENDER: Liu, Zhongyi In accordance with provisions of Contract Law of the Peoples Republic of China and Bank of China, after reviewing the status and the request of the Borrower, the Lender agrees to grant the Borrower a line of credit on 10,030,224.90 RMB. The Borrower and Lender through friendly negotiation, h |
|
| October 5, 2006 |
EX-99.24 27 v054112ex99-24.htm LOAN CONTRACT Contract Number: BORROWER: Beijing En Ze Jia Shi Pharmaceutical Co., Ltd LENDER: Ma, Zhaozhao In accordance with provisions of Contract Law of the Peoples Republic of China and Bank of China, after reviewing the status and the request of the Borrower, the Lender agrees to grant the Borrower a line of credit on 4,527,624.56 RMB. The Borrower and Lender t |
|
| October 5, 2006 |
EX-99.4 5 v054112ex99-4.htm Proxy Agreement This Proxy Agreement (the “Agreement”) is entered into as of September 6, 2006 among the following parties: Party A: Lotus Pharmaceutical InternationalôInc. Registered Address: Boca Corporate Plaza, 7900 Glades Road, Suite 420, Boca Raton, Florida 33434, the United States of America Chairman: Liu Zhongyi Party B: The undersigned three shareholders of Lia |
|
| October 5, 2006 |
OPERATING AGREEMENT (English Translation) EX-99.8 9 v054112ex99-8.htm OPERATING AGREEMENT (English Translation) This Operating Agreement (this “Agreement”) is dated September 6, 2006, and is entered into in Beijing, China by and among Lotus Pharmaceutical International, Inc., a company incorporated under the laws of the State of Nevada, the United States, located at Boca Corporate Plaza, 7900 Glades Road, Suite 420, Boca Raton, Florida 33 |
|
| October 5, 2006 |
BILL OF SALE This Bill of Sale is delivered pursuant to that certain Share Exchange Agreement dated September 6, 2006 (the “Agreement”), by and among shareholders of Lotus Pharmaceutical International, Inc. |
|
| October 5, 2006 |
LEASE CONTRACT Lesser (hereinafter referred to as Party A): Construction and Repair Agency of Haiying Group, China Lessee (hereinafter referred to as Party B): Liangfang Pharmaceutical Co. |
|
| October 5, 2006 |
EX-99.19 22 v054112ex99-19.htm LEASE CONTRACT Lesser (hereinafter referred to as Party A): Beijing Xingfa Food Shop Lessee (hereinafter referred to as Party B): Liangfang Pharmaceutical Co. Ltd Party A and Party B have reached an agreement through friendly consultation to conclude the following contract. 1. Location of the premises Party A will lease to Party B the premises and attached facilities |
|
| October 5, 2006 |
LOAN CONTRACT Contract Number: BORROWER: Beijing En Ze Jia Shi Pharmaceutical Co., Ltd LENDER: Song, Guo’an In accordance with provisions of Contract Law of the Peoples Republic of China and Bank of China, after reviewing the status and the request of the Borrower, the Lender agrees to grant the Borrower a line of credit on 14,700,000 RMB. The Borrower and Lender through friendly negotiation have |
|
| October 5, 2006 |
CONSULTING SERVICES AGREEMENT (English Translation) EX-99.6 7 v054112ex99-6.htm CONSULTING SERVICES AGREEMENT (English Translation) This Consulting Services Agreement (this “Agreement”) is dated September 6, 2006, and is entered into in Beijing, China between Lotus Pharmaceutical International, Inc., a company incorporated under the laws of the State of Nevada, the United States, located at Boca Corporate Plaza, 7900 Glades Road, Suite 420, Boca Ra |
|
| October 5, 2006 |
OPTION AGREEMENT (English translation) OPTION AGREEMENT (English translation) This Operating Agreement (this “Agreement”) is dated September 6, 2006, and is entered into in Beijing, China between Lotus Pharmaceutical International, Inc. |
|
| October 5, 2006 |
EQUITY PLEDGE AGREEMENT (English Translation) EQUITY PLEDGE AGREEMENT (English Translation) This Equity Pledge Agreement (hereinafter this ?Agreement?) is dated September 6, 2006, and is entered into in Beijing, China between Lotus Pharmaceutical International, Inc. |
|
| October 5, 2006 |
LEASE CONTRACT Lesser (hereinafter referred to as Party A): Beijing Fengtai District Retired Officer Management Agency of General Logistics of P. |
|
| October 5, 2006 |
LEASE CONTRACT Lesser (hereinafter referred to as Party A): Beijing South Palace marketing center Lessee (hereinafter referred to as Party B): Liangfang Pharmaceutical Co. |
|
| October 5, 2006 |
LOAN CONTRACT Contract Number: BORROWER: Beijing En Ze Jia Shi Pharmaceutical Co., Ltd LENDER: Zheng, Guixin In accordance with provisions of Contract Law of the Peoples Republic of China and Bank of China, after reviewing the status and the request of the Borrower, the Lender agrees to grant the Borrower a line of credit on 11,305,000 RMB. The Borrower and Lender through friendly negotiation, hav |
|
| October 5, 2006 |
S.E. ASIA TRADING COMPANY, INC. 1545 E. Interstate 30 Rockwall, Texas 75087 EX-99.28 31 v054112ex99-28.htm S.E. ASIA TRADING COMPANY, INC. 1545 E. Interstate 30 Rockwall, Texas 75087 September 13, 2006 Mr. Charles Smith 1545 E. Interstate 30 Rockwall, TX 75087 Re: S. E. Asia Trading Company, Inc.’s Line of Credit and Building Lease Dear. Mr. Smith: This letter agreement (this “Letter Agreement”) shall confirm our understanding with respect to certain matters in connection |
|
| October 5, 2006 |
CONSULTING SERVICES AGREEMENT (English Translation) CONSULTING SERVICES AGREEMENT (English Translation) This Consulting Services Agreement (this ?Agreement?) is dated September 6, 2006, and is entered into in Beijing, China between Lotus Pharmaceutical International, Inc. |
|
| September 20, 2006 |
S.E. ASIA TRADING COMPANY, INC. 1545 E. Interstate 30 Rockwall, Texas 75087 INFORMATION STATEMENT PURSUANT TO SECTION 14(F) OF THE SECURITIES EXCHANGE ACT OF 1934 AND SEC RULE 14F-1 NOTICE OF CHANGE IN THE COMPOSITION OF THE BOARD OF DIRECTORS September 19, 2006 This Information Statement is being furnished to holders of record of the common stock, $.001 par value per share, of S.E. Asia Trading C |
|
| September 7, 2006 |
EX-10.1 2 v052232ex10-1.htm SHARE EXCHANGE AGREEMENT by and among Lotus Pharmaceutical International, Inc. a Nevada corporation and the Shareholders of Lotus Pharmaceutical International, Inc., on the one hand; and S.E. Asia Trading Company, Inc., a Nevada corporation, and the Majority Shareholders of S.E. Asia Trading Company, Inc., on the other hand September 6, 2006 SHARE EXCHANGE AGREEMENT Thi |
|
| September 7, 2006 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act September 6, 2006 Date of Report (Date of Earliest Event Reported) S. |
|
| August 14, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission file number 001-32581 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2006 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tr |
|
| March 31, 2006 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act For the Fiscal Year Ended December 31, 2005 S. |
|
| February 28, 2006 |
INFORMATION STATEMENT PURSUANT TO SECTION 14 (C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [] Preliminary information statement [ ] Confidential, for Use of the Commission Only [ X ] Definitive information statement S. |
|
| February 14, 2006 |
S.E. Asia Trading Company, Inc. PRE 14C 2/13/06 INFORMATION STATEMENT PURSUANT TO SECTION 14 (C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ X ] Preliminary information statement [ ] Confidential, for Use of the Commission Only [ ] Definitive information statement S.E. ASIA TRADING COMPANY, INC. (NAME OF COMPANY AS SPECIFIED IN ITS CHARTER) Payment of Filing Fee (Check the |
|
| January 12, 2006 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act January 9, 2006 Date of Report (Date of Earliest Event Reported) S. |
|
| January 6, 2006 |
INFORMATION STATEMENT PURSUANT TO SECTION 14 (C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary information statement [ ] Confidential, for Use of the Commission Only [ X ] Definitive information statement S. |
|
| December 27, 2005 |
INFORMATION STATEMENT PURSUANT TO SECTION 14 (C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ X ] Preliminary information statement [ ] Confidential, for Use of the Commission Only [ ] Definitive information statement S. |
|
| November 10, 2005 |
QUARTERLY REPORT FOR SMALL BUSINESS ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 25, 2005 |
S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 U.S. Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549-0303 Re: FILE NUMBER(S): 001-32581 Dear Sir or Madam: The Registrant hereby requests the immediate withdrawal of the above numbered file. The document was mistakenly filed as an 8-A12B when in fact it should have been filed |
|
| July 25, 2005 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 S. E. ASIA TRADING COMPANY, INC. (Exact name of registrant as specified in its charter) Nevada 20-0507918 (State of incorporation or organization) (I.R.S. Employer Identification Number) 1545 E. Interstate 30, R |
|
| July 22, 2005 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 S. E. ASIA TRADING COMPANY, INC. (Exact name of registrant as specified in its charter) Nevada 20-0507918 (State of incorporation or organization) (I.R.S. Employer Identification Number) 1545 E. Interstate 30, R |
|
| June 16, 2005 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 10-KSB/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act For the Fiscal Year Ended December 31, 2004 S. |
|
| June 10, 2005 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [ X ]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2005 OR [ ]TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 333-118898 S.E. ASIA TRADING COMPANY, INC. |
|
| June 10, 2005 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act For the Fiscal Year Ended December 31, 2004 S. |
|
| December 27, 2004 |
S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 December 22, 2004 Mr. Pradip Bhaumik U.S. Securities & Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: S.E. Asia Trading Company, Inc. Form SB-1 File No. 333-118898 Dear Mr. Bhaumik: Out letter dated December17, 2004, requesting acceleration of the effectiveness of our registration statement |
|
| December 27, 2004 |
S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 December 22, 2004 Mr. Pradip Bhaumik U.S. Securities & Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: S.E. Asia Trading Company, Inc. Form SB-1 File No. 333-118898 Dear Mr. Bhaumik: Pursuant to Rule 461(a) of the Securities Act of 1933, the undersigned hereby requests acceleration of the ef |
|
| December 27, 2004 |
S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 December 17, 2004 Mr. Pradip Bhaumik U.S. Securities & Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: S.E. Asia Trading Company, Inc. Form SB-1 File No. 333-118898 Dear Mr. Bhaumik: Pursuant to Rule 461(a) of the Securities Act of 1933, the undersigned hereby requests acceleration of the ef |
|
| December 17, 2004 |
S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 December 17, 2004 Mr. Pradip Bhaumik Ms. Ellie Quarles Mr. H. Christopher Owings U.S. Securities & Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: S.E. Asia Trading Company, Inc. Form SB-1 File No. 333-118898 Dear Mr. Bhaumil, Ms. Quarles and Mr. Owings: Following are responses to your comme |
|
| December 3, 2004 |
S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 CORRESP 1 filename1.htm S.E. Asia Trading Company, Inc. 1545 E. Interstate 30 Rockwall, Texas 75087 (972) 722-3300 December 2, 2004 Mr. Pradip Bhaumik Ms. Ellie Quarles Mr. H. Christopher Owings U.S. Securities & Exchange Commission 450 Fifth Street NW Washington, DC 20549 RE: S.E. Asia Trading Company, Inc. Form SB-1 File No. 333-118898 Dear Mr. Bhaumil, Ms. Quarles and Mr. Owings: Following are |
